Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lethal Congenital Contracture Syndrome 2 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumor Cancers 1Recurrence 1Pancreatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × seribantumab × Clear all
NCT01447706 2016-05-12

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Merrimack Pharmaceuticals

Phase 2 Completed
223 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡